TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06793982
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
Study: NCT06795594
Drug: sufentanil 2 µg/kg + ondansetron 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient-controlled analgesia (PCA) pump held a solution of 2 µg/kg sufentanil and 0.2 mg/kg ondansetron in 100 ml. It infused 2 ml/hour continuously, allowing patients to self-administer an extra 2 ml bolus every 15 minutes if needed. For inadequate pain control, diclofenac sodium suppositories were used as rescue analgesia, depending on individual pain assessments and the requirement for extra relief.
Study: NCT06795620
Drug: Adipose tissue derived mesenchymal Stroma/stem Cells transplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb (dose of 90x10\^6 AdMSC) of patients. They will be followed at 1 day, 7 days, 30 days, 90 days, and 180 days after the injection.
Study: NCT06472219
Drug: Prednisolone 30 mg
Normalized name: prednisolone 30 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a glucocorticoid like cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic and vasoconstrictive effects. It binds to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. It has a short duration of action as the half-life is 2.1-3.5 hours and 98% is eliminated in urine. On 21 June 1955 it was granted FDA approval.
Study: NCT06472219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This a tablet identical to prednisolone.
Study: NCT05765877
Drug: WX-0593 Tablets
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
Study: NCT06794957
Drug: AL8326 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/tablet;Oral administration, once daily.
Study: NCT06287463
Drug: DCC-3084
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06788704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient recive placebo once daily early post turp
Study: NCT06034470
Drug: Pivekimab Sunirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06794372
Drug: [68Ga]Ga-FAPI-46 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]Ga-FAPI-46 PET/CT
Study: NCT05648968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion, prepared from matching placebo
Study: NCT06474455
Drug: SHR-9839 ；SHR-A2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-9839 combined with SHR-A2009
Study: NCT06474455
Drug: SHR-9839 ； SHR-A1921
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-9839 combined with SHR-A1921
Study: NCT06281132
Drug: CKD-341, D956
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 1 tablet under fasting condition
Study: NCT06118866
Drug: placebo-Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 0mg，SC，Q2W，12 cycles
Study: NCT06118866
Drug: HMI-115, 240mg-Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMI-115, 240mg，SC，Q2W，12 cycles
Study: NCT05495815
Drug: Indefinite SAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indefinite oral suppressive antibiotic therapy
Study: NCT06245889
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: additional chemotherapy - neoadjuvant or adjuvant rescue
Study: NCT06245889
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: additional chemotherapy - adjuvant rescue
Study: NCT06245889
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: adjuvant rescue
Study: NCT05525416
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigators will give three incremental doses via brachial artery catheter to observe adrenoreceptor activation. This will occur three times throughout the protocol.
Study: NCT06797375
Drug: RLYB116 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLYB116 is a small protein composed of an Affibody® Z-domain that binds with high affinity to C5, inhibiting terminal complement activation, and an albumin binding domain (ABD) that extends the effective plasma half-life of the protein by targeting serum albumin.
Study: NCT06788587
Drug: Placebo plus TAU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive once daily LDX-01-matched placebo for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25).
Study: NCT00000758
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06428903
Drug: ADC189 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
Study: NCT06428903
Drug: ADC189 granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)
Study: NCT06428903
Drug: ADC189 180mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
Study: NCT05388877
Drug: MEK-1/MEKK-1 Inhibitor E6201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05278208
Drug: LUTATHERA® (Lutetium Lu 177 dotatate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
Study: NCT05870995
Drug: CALGE-VEN- RIC-conditioning
Normalized name: Apis mellifera ven protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
Study: NCT06796504
Drug: Disease-Modifying Therapies (DMTs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will continue treatment with standard of care disease-modifying therapies for he duration of the study.
Study: NCT05414136
Drug: BAT1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids
Study: NCT04958122
Drug: benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Study: NCT05534750
Drug: Standard quadruple therapy arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms.
Study: NCT04762641
Drug: ABL503
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
Study: NCT06636500
Drug: CG001419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses
Study: NCT06219174
Drug: Difluoromethylornithine
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Level -1: 4500 mg/m2 by mouth (PO) daily Dose Level 1: 6750 mg/m2 by mouth (PO) daily Dose Level 2: 9000 mg/m2 by mouth (PO) daily
Study: NCT06636227
Drug: Diclofenac 100mg
Normalized name: diclofenac sodium 100 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac 100mg
Study: NCT06636227
Drug: Diclofenac 75mg
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac 75mg
Study: NCT06636227
Drug: Diclofenac 50mg
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac 50mg
Study: NCT06636227
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT06204237
Drug: [89Zr]Zr-DFO-APAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a single i.v. injection of \[89Zr\]Zr-DFO-APAC 15 MBq (Megabecquerel).
Study: NCT04930445
Drug: Oxbryta® (voxelotor) 500mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
Study: NCT05672784
Drug: standard analgesia (paracetamol and meloxicam)
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: (paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.
Study: NCT05494788
Drug: CardiolRx
Normalized name: CARDIOTEX RX TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutically produced Cannabidiol
Study: NCT06010719
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral azithromycin (20 mg/kg, single directly observed dose, oral suspension),
Study: NCT06794086
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens based on fluorouracil (5-FU), such as CAPOX with a 3-week cycle or mFOLFOX6/FOLFIRI/FOLFOXIRI with a 2-week cycle, may be combined with targeted therapy. During chemotherapy or chemoradiotherapy, optimal supportive care will be provided.
Study: NCT06797401
Drug: RBD5044
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBD5044, active drug.
Study: NCT06795204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Control
Study: NCT06572111
Drug: BI 1839100 (C-14) formulation 1
Normalized name: TRIOLEIN, 1-C-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1839100 (C-14) formulation 1
Study: NCT04607005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
Study: NCT04607005
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to receive Standard of care as they are used to before entry in the study.
Study: NCT06788158
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program in which 2 ml of dexamethasone will be administered in an 8 mg/2 ml ampoule diluted in 2 ml of lidocaine injectable solution in a 50 ml bottle (20 mg/ml) in a single application at 1 point, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
Study: NCT06796517
Drug: Proteasome Inhibitor
Normalized name: Proteasome inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.
Study: NCT06796517
Drug: IMiD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
Study: NCT06483880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the placebo, which will be starch tablets in the same dosage of albendazole.
Study: NCT06794502
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine from butterfly pea flower decocta extract is used as an additional TB drug therapy regimen for active TB patients during the initiation phase of treatment for 2 months.
Study: NCT06791993
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an inert placebo capsule that matches the probiotic capsule in size, shape, and color. The placebo will be administered orally twice daily, starting 2 weeks before surgery and continuing for 2 weeks postoperatively.
Study: NCT02915198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo
Study: NCT06793553
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
Study: NCT05329623
Drug: JDQ443
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the participants will receive a single oral dose of JDQ443.
Study: NCT06679140
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets
Study: NCT04720183
Drug: GLPG3970
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state.
Study: NCT04998604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection subcutaneous
Study: NCT06793150
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
Study: NCT05819658
Drug: GV1001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT05819658
Drug: GV1001 0.56mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized peptide from hTERT
Study: NCT05819658
Drug: GV1001 1.12mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized peptide from hTERT
Study: NCT05794321
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.
Study: NCT06789549
Drug: epinephrine nasal drops
Normalized name: epinephrine Nasal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in experimental arms received 1 mL of 0.1% epinephrine nasal drops before nasotracheal intubation
Study: NCT06640933
Drug: BIIB091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05785624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as per the schedule specified in the respective arms.
Study: NCT04847544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally BID for up to 28 days.
Study: NCT06291376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo via weight-based IV infusion.
Study: NCT06789913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLY-2608 matched-placebo
Study: NCT06793670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of saline solution of NaCl 0.9%
Study: NCT06793371
Drug: Placebo to match CK-4021586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally
Study: NCT05027230
Drug: STSP-0601 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
Study: NCT05900986
Drug: LS301-IT 0.025 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
Study: NCT06628362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be volume-matched and administered subcutaneously (SC) once weekly.
Study: NCT05900986
Drug: LS301-IT 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
Study: NCT05900986
Drug: LS301-IT 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
Study: NCT05900986
Drug: LS301-IT 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
Study: NCT05048134
Drug: HRS2300
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS2300 monotherapy
Study: NCT05048134
Drug: HRS2300、 SHR-1316
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS2300 combined with SHR-1316
Study: NCT05048134
Drug: HRS2300、SHR-1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS2300 combined with SHR-1701
Study: NCT05380427
Drug: CU-40101
Normalized name: Cu 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
Study: NCT06494683
Drug: Pueraria lobata radix
Normalized name: Pueraria montana var. lobata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
Study: NCT05473195
Drug: BVL-GSK098 9mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
Study: NCT05919082
Drug: LEO 90100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
Study: NCT05919082
Drug: Daivobet® ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
Study: NCT04637763
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for lymphodepletion
Study: NCT06653907
Drug: Levothyroxine Sodium (LT4) Tablets
Normalized name: Levothyroxine Sodium Tablets
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in our study will determine the dosage of L-T4 based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery.
Study: NCT06653907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in our study will determine the dosage of placebo based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery.
Study: NCT05183490
Drug: Rapidly generated virus specific T (R-MVST) cells
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg